Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
Open Access
- 1 March 2011
- journal article
- molecules of-the-millennium
- Published by SAGE Publications in Journal of Pharmacology and Pharmacotherapeutics
- Vol. 2 (1), 49-51
- https://doi.org/10.4103/0976-500x.77118
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Oral fingolimod for the treatment of relapsing-remitting multiple sclerosisDrugs of Today, 2010
- IMMUNOLOGY OF MULTIPLE SCLEROSISAnnual Review of Immunology, 2005
- FTY720: Sphingosine 1-Phosphate Receptor-1 in the Control of Lymphocyte Egress and Endothelial Barrier FunctionAmerican Journal of Transplantation, 2004
- Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1Nature, 2004
- The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate ReceptorsPublished by Elsevier BV ,2002
- Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor AgonistsScience, 2002
- Multiple sclerosisThe Lancet, 2002
- The prevalence of multiple sclerosis in the world: an updateNeurological Sciences, 2001
- Multiple SclerosisNew England Journal of Medicine, 2000
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998